Navigation Links
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Date:5/31/2008

- Data From Phase 3 Study Presented at ASCO -

COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced results of a three-arm phase 3 clinical trial that show patients with relapsed and/or refractory mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, treated with the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) experienced a statistically significant improvement in median progression-free survival (PFS), compared with single-agent therapy selected by the investigator (4.8 months vs. 1.9 months, P=0.0009). These results are being presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"Relapsed/refractory mantle cell lymphoma is extremely difficult to treat, and this is the first comparative phase 3 study to show a significant improvement in progression-free survival for these patients," says Georg Hess, M.D., Johannes Gutenberg-Universitat, Mainz, Germany. "These data further support the antitumor activity seen in phase 2 studies of temsirolimus in relapsed/refractory mantle cell lymphoma and indicate that mTOR inhibition may be a viable approach in this disease area."

MCL accounts for approximately 6 percent of non-Hodgkin's lymphoma cases.

"These findings reinforce the clinical potential of mTOR inhibition with TORISEL. Wyeth is committed to the continued exploration of mTOR inhibition with TORISEL for the treatment of a variety of cancers," says Joseph S. Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals.

TORISEL was approved in May 2007 for the treatment of advanced renal cell carcinoma (RCC) and is the only
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
3. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
4. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
7. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
10. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
11. Tailored Clopidogrel Dosing Improves PCI Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... ... technology, CHICAGO, March 30 ... balloons and stents,to open a completely blocked coronary artery and restore ... attack when performed rapidly.,However, few hospitals can meet the 90-minute treatment ...
... drug appears ... unnecessary, ... improvements in percutaneous coronary,intervention (PCI) for patients with heart attack, among ... unwanted blood clotting. Now a new study has found that high,loading ...
Cached Medicine Technology:Is PCI Safe, Effective After Clot-Busters for Heart Attack? 2Is PCI Safe, Effective After Clot-Busters for Heart Attack? 3BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack 2BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack 3
(Date:4/24/2014)... better understanding of drug interactions, which are a major ... two or more medications are taken at the same ... the other. Similarly, one drug may magnify the ... major cause of illness and hospitalization. However, there ... drug studies in humans. Limits come in part ...
(Date:4/24/2014)... coated with an antimicrobial peptide could help to lower the ... Optometry and Vision Science , official journal of ... is published by Lippincott Williams & Wilkins , a ... animals and now humans support the biocompatibility and safety of ... new research by Debarun Dutta, B.Optom, of The University of ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... End-of-life aspects, the corresponding terminology, and the relevance ... considered in publications on randomized controlled trials (RCTs). ... the German Institute for Quality and Efficiency in ... as final report. , Together with external experts, ... examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... & Experimental Allergy reveals that there is no association between ... confidence in being able to provide a safe meal to a ... and as much as 8% of children in the UK alone. ... serious being anaphylaxis, which can cause death. Led by Professor Helen ...
... care improves medical outcomes, investigators from the Regenstrief ... providing a call to action for the training ... well as the burgeoning scientific knowledge needed to ... the Patient-Centered Divide: Transforming Health Care Quality Through ...
... Material (SRM) from the National Institute of Standards ... accurately diagnose Huntington,s disease, an inherited degenerative brain ... 50 and progressively leads to physical impairment, dementia ... developed Huntington,s disease has a 50-50 chance of ...
... in French and Spanish . , ... professors Antonio Campos and Miguel Alaminos (histologists), Mara del Mar ... and the ophthalmologist Miguel Gonzlez Andrades, University Hospital San Cecilio, ... Researchers extracted pig corneal cells and replaced them with human ...
... available in French . Montreal, April 13, ... in Tourette syndrome may be as effective as and even ... study published in a special edition of the International Journal ... of the Louis-H. Lafontaine Hospital affiliated with Universit de Montral, ...
... For the first time, scientists at Toronto General Hospital, ... that the Toronto XVIVO System can safely and effectively ... lungs so that they can be successfully transplanted into ... the donor organ pool and improve outcomes after transplantation. ...
Cached Medicine News:Health News:Training future doctors to enlist patients as partners in care 2Health News:New NIST SRM helps improve diagnosis of Huntington's disease 2Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 3Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 4
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Cross action serrated handle with polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
Oval solid 24 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 20 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish....
Medicine Products: